financetom
Business
financetom
/
Business
/
Market Chatter: Citigroup, Goldman Sachs Hired for IPO of Titan Cement's US Unit
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Citigroup, Goldman Sachs Hired for IPO of Titan Cement's US Unit
Sep 6, 2024 1:15 PM

02:49 PM EDT, 09/05/2024 (MT Newswires) -- Citigroup ( C ) and Goldman Sachs (GS) were hired to help arrange a planned listing of Titan Cement's US business next year, Bloomberg reported Thursday, citing people familiar with the matter.

Titan Cement plans to raise at least $500 million by selling a minority stake through the IPO of Titan America, the report said.

Titan America could fetch a valuation of over $2 billion via the listing, according to the people.

Representatives for Titan Cement, Citigroup ( C ) and Goldman declined Bloomberg's requests for comment.

Citigroup ( C ) declined MT Newswires' request for comment, while Titan Cement and Goldman did not immediately reply.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 60.75, Change: -0.21, Percent Change: -0.34

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Tonix Pharmaceuticals (TNXP) Stock Is Falling
Why Tonix Pharmaceuticals (TNXP) Stock Is Falling
Jul 8, 2024
Tonix Pharmaceuticals Holding Corp ( TNXP ) shares are trading lower by 11.3% to $0.71 during Monday’s session after the company announced receipt of the formal minutes from a recent pre-New Drug Application meeting with the FDA for Tonmya for the management of fibromyalgia. What Happened? Tonix Pharmaceuticals ( TNXP ) earlier Monday announced that it received formal minutes from...
SolarEdge Technologies Inventory, Demand Headwinds to Taper Off in 2025, BofA Says
SolarEdge Technologies Inventory, Demand Headwinds to Taper Off in 2025, BofA Says
Jul 8, 2024
12:24 PM EDT, 07/08/2024 (MT Newswires) -- SolarEdge Technologies' ( SEDG ) current share price slump is factoring in an unlikely worst-case scenario of inventory writedowns and liquidity challenges, BofA Securities said in a note Monday. Residential demand is softening and the European market is still facing substantial inventory headwinds. There is a concern that inventory congestion and reduced sales...
TD's chief compliance officer departs amid US anti-money laundering probe
TD's chief compliance officer departs amid US anti-money laundering probe
Jul 8, 2024
TORONTO (Reuters) - TD Bank's chief compliance officer has left the bank, according to a memo sent internally, at a time the Canadian lender faces U.S. regulators and the Justice Department in a probe related to its anti-money laundering program. Monica Kowal, who joined the bank in 2017, left the company this week, and will be replaced by Deputy Chief...
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer
Jul 8, 2024
Monday, IDEAYA Biosciences Inc ( IDYA ) released clinical data for the IDE397 Phase 2 monotherapy expansion dose in methylthioadenosine phosphorylase-deletion urothelial and non-small cell lung cancer patients (NSCLC). “IDE397 is a potential first-in-class MAT2A inhibitor, that is being advanced as a monotherapy agent in priority MTAP-deletion solid tumor types and in high conviction rational combinations, including with Amgen’s investigational...
Copyright 2023-2026 - www.financetom.com All Rights Reserved